Phosphorylcholine
|
Basic information |
| Metabolite name | Phosphorylcholine |
 | HMDB0001565 |
 |
C00588 |
 |
1014 |
| Synonyms | Phosphocholine; |
| No. of studies | 28 |
|
Basic information |
| Metabolite name | Phosphorylcholine |
| HMDB0001565 |
|
C00588 |
|
1014 |
| Synonyms | Phosphocholine; |
| No. of studies | 28 |
|
Relationship between Phosphorylcholine and depression (count: 28) |
| Study | Study Type  |
Comparison groups | Tissue | Organism | Up/Down regulated |
| Study M033 | Type3 | paroxetine group vs. control group | Hippocampus | DBA/2OlaHsd mouse | Down |
| Study M044 | Type3 | control + rTMS group vs. control + sham rTMS group | Prefrontal cortex | Sprague-Dawley rat | Up |
| Study M057 | Type1 | sCSDS group vs. control group | Liver | C57BL/6JJmsSlc mouse | Up |
| Study M076 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M076 | Type2 | CUMS + fluoxetine group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M076 | Type2 | CUMS + Lilium saponins group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M076 | Type2 | CUMS + Anemarrhena saponins group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M086 | Type5 | paroxetine-treated responder group vs. non-responder group | Hippocampus | DBA/2J mouse | Up |
| Study M103 | Type1 | stress group vs. control group | Plasma | C57BL/6 mouse | Unknown |
| Study M107 | Type1 | Glu group vs. control group | PC12 cell | Rat | Down |
| Study M107 | Type1 | CORT group vs. control group | PC12 cell medium | Rat | Up |
| Study M107 | Type1 | CORT group vs. control group | PC12 cell | Rat | Up |
| Study M107 | Type1 | Glu group vs. control group | PC12 cell medium | Rat | Down |
| Study M1090 | Type2 | CUMS + hyperbaric oxygen treatment group vs. CUMS group | Plasma | BALb/c mouse | Up |
| Study M1090 | Type3 | hyperbaric oxygen treatment group vs. control group | Plasma | BALb/c mouse | Down |
| Study M1102 | Type1 | nitenpyram group vs. control group, male offspring | Faece | ICR mouse | Down |
| Study M114 | Type3 | venlafaxine group vs. control group | Astrocyte | Sprague-Dawley rat | Up |
| Study M115 | Type1 | MDD group vs. control group | Plasma | Human | Up |
| Study M208 | Type1 | GCI model group vs. control group | Hippocampus | ICR mouse | Down |
| Study M313 | Type1 | depression group vs. control group | Temporal lobe | Human | Up |
| Study M313 | Type1 | depression group vs. control group | Cerebellum | Human | Up |
| Study M313 | Type1 | depression group vs. control group | Hippocampus | Human | Up |
| Study M313 | Type1 | depression group vs. control group | Insula | Human | Up |
| Study M460 | Type1 | depressed group vs. control group | Liver | Kunming mouse | Up |
| Study M486 | Type1 | CORT group vs. control group | PC12 cell | Rat | Up |
| Study M555 | Type1 | FMT group vs. control group | Liver | Sprague-Dawley rat | Up |
| Study M592 | Type1 | CUMS group vs. control group, NMR | Liver | Sprague-Dawley rat | Down |
| Study M595 | Type1 | CRS group vs. control group | Nucleus accumbens | C57BL/6J mouse | Down |
| Study M595 | Type2 | CRS + acetyl-L-carnitine group vs. CRS group | Nucleus accumbens | C57BL/6J mouse | Up |
| Study M631 | Type1 | CUMS group vs. control group | Serum | Kunming mouse | Down |
| Study M631 | Type2 | CUMS + high dose of iridoid-rich fraction of V. jatamansi group vs. CUMS group | Serum | Kunming mouse | Up |
| Study M632 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Unknown |
| Study M680 | Type1 | 5-fluorouracil group vs. control group | Prefrontal cortex | Sprague-Dawley rat | Up |
| Study M740 | Type1 | CUMS group vs. control group | Gastrocnemius muscle | Sprague-Dawley rat | Down |
| Study M740 | Type1 | CUMS group vs. control group | Soleus muscle | Sprague-Dawley rat | Down |
| Study M740 | Type2 | CUMS + endurance exercise group vs. CUMS group | Soleus muscle | Sprague-Dawley rat | Up |
| Study M740 | Type2 | CUMS + endurance exercise group vs. CUMS group | Gastrocnemius muscle | Sprague-Dawley rat | Up |
| Study M772 | Type1 | CUMS group vs. control group | Amygdala | Sprague-Dawley rat | Down |
| Study M809 | Type1 | CUMS group vs. control group | Serum | Kunming mouse | Up |
| Study M809 | Type2 | CUMS + Milletia speciosa Champ group vs. CUMS group | Serum | Kunming mouse | Down |
| Study M840 | Type1 | A1/A2 beta-casein group vs. control group | Frontal cortex | Wistar rat | Up |
| Study M846 | Type2 | postpartum depression model + 919 syrup group vs. postpartum depression model group | Hippocampus | BALB/c mouse | Down |
| Study M955 | Type1 | CUMS group vs. control group | Hippocampus | C57BL/6J mouse | Up |
| Study M955 | Type2 | CUMS + deoiled and dechlorogenic acid-enriched sunflower seeds group vs. CUMS group | Hippocampus | C57BL/6J mouse | Down |
| Study M955 | Type2 | CUMS + tryptophan-enriched whey protein-based group vs. CUMS group | Hippocampus | C57BL/6J mouse | Down |
| Study M955 | Type2 | CUMS + deoiled sunflower seeds group vs. CUMS group | Hippocampus | C57BL/6J mouse | Down |
| Study M981 | Type2 | Abeta oligomer + involuntary and voluntary running + acousto-optic stimulation group vs. Abeta oligomer group | Serum | ICR mouse | Down |